PE20231094A1 - Composicion que contiene un derivado de arilamida - Google Patents
Composicion que contiene un derivado de arilamidaInfo
- Publication number
- PE20231094A1 PE20231094A1 PE2023000098A PE2023000098A PE20231094A1 PE 20231094 A1 PE20231094 A1 PE 20231094A1 PE 2023000098 A PE2023000098 A PE 2023000098A PE 2023000098 A PE2023000098 A PE 2023000098A PE 20231094 A1 PE20231094 A1 PE 20231094A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- composition
- refers
- pharmaceutically acceptable
- general formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Refiere a una composicion que comprende el compuesto de formula general (1): 2-(4-ciclopropil-2-fluoroanilino)-3,4-difluoro-5-[[3-fluoro-2-(metilsulfamoilamino)piridin-4-il]metil]benzamida, o una sal farmaceuticamente aceptable del mismo, o un solvato farmaceuticamente aceptable del compuesto o sal; y un dispersante (por ejemplo, metilcelulosa) y/o un compuesto alcalino (por ejemplo, meglumina). En dicho compuesto, el anillo A esta representado por la formula general (2), (3), (4) y (5) en donde , y representan enlaces que se unen a ?NH?, ?CONH? y ?CH2? respectivamente; X1, X2, X3, X4, X5 y X6 representan independientemente ?CR2= o ?N=; R1 es ?S(=O)2?NH?R8 o ?S(=O)2?R8; R3, R5, R4 y R6 se seleccionan de alquilo C1-6, cicloalquilo C3-6, entre otros; asimismo, R4 y R6 forman un heteroanillo insaturado de 5 miembros junto a los atomos de carbono con los que se enlazan. Dicha composicion tiene una actividad de estabilizacion de complejos RAF/MEK y/o actividad de inhibicion de MEK. Tambien, refiere a su utilidad para el tratamiento o prevencion de un trastorno de proliferacion celular como el cancer y a metodos para producir dicha composicion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020125822 | 2020-07-22 | ||
PCT/JP2021/027316 WO2022019329A1 (ja) | 2020-07-22 | 2021-07-21 | アリールアミド誘導体を含む組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20231094A1 true PE20231094A1 (es) | 2023-07-18 |
Family
ID=79729189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2023000098A PE20231094A1 (es) | 2020-07-22 | 2021-07-21 | Composicion que contiene un derivado de arilamida |
Country Status (16)
Country | Link |
---|---|
US (1) | US20230270730A1 (es) |
EP (1) | EP4186506A1 (es) |
JP (2) | JP7022873B1 (es) |
KR (2) | KR20230122174A (es) |
CN (1) | CN115803024A (es) |
AU (1) | AU2021311665A1 (es) |
BR (1) | BR112023000883A2 (es) |
CA (1) | CA3186655A1 (es) |
CL (1) | CL2023000199A1 (es) |
CR (1) | CR20230095A (es) |
IL (1) | IL300051A (es) |
MX (1) | MX2023000857A (es) |
PE (1) | PE20231094A1 (es) |
TW (1) | TW202216140A (es) |
WO (1) | WO2022019329A1 (es) |
ZA (1) | ZA202302083B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
JPWO2022018875A1 (es) * | 2020-07-22 | 2022-01-27 | ||
IL307964A (en) * | 2021-06-09 | 2023-12-01 | Chugai Pharmaceutical Co Ltd | Combined treatment for cancer |
WO2023204259A1 (ja) * | 2022-04-20 | 2023-10-26 | 中外製薬株式会社 | がんの治療又は予防用医薬 |
WO2024002210A1 (zh) * | 2022-06-30 | 2024-01-04 | 上海喆邺生物科技有限公司 | 一种芳香酰胺类衍生物及其在抗肿瘤药物中的应用 |
WO2024010925A2 (en) * | 2022-07-08 | 2024-01-11 | Nested Therapeutics, Inc. | Mitogen-activated protein kinase (mek) inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1674452A4 (en) * | 2003-09-19 | 2007-10-10 | Chugai Pharmaceutical Co Ltd | NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR |
SI1682138T1 (sl) * | 2003-11-19 | 2011-04-29 | Array Biopharma Inc | HETEROCIKLIÄŚNI INHIBITORJI MEK-a |
TWI361066B (en) | 2004-07-26 | 2012-04-01 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
EP2491014A1 (en) * | 2009-10-21 | 2012-08-29 | Bayer Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
AR121078A1 (es) * | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
-
2021
- 2021-07-21 US US18/016,691 patent/US20230270730A1/en active Pending
- 2021-07-21 KR KR1020237026764A patent/KR20230122174A/ko active Application Filing
- 2021-07-21 CN CN202180047812.XA patent/CN115803024A/zh active Pending
- 2021-07-21 PE PE2023000098A patent/PE20231094A1/es unknown
- 2021-07-21 BR BR112023000883A patent/BR112023000883A2/pt unknown
- 2021-07-21 CA CA3186655A patent/CA3186655A1/en active Pending
- 2021-07-21 EP EP21845639.0A patent/EP4186506A1/en active Pending
- 2021-07-21 IL IL300051A patent/IL300051A/en unknown
- 2021-07-21 CR CR20230095A patent/CR20230095A/es unknown
- 2021-07-21 KR KR1020227043065A patent/KR102566299B1/ko active IP Right Grant
- 2021-07-21 AU AU2021311665A patent/AU2021311665A1/en active Pending
- 2021-07-21 MX MX2023000857A patent/MX2023000857A/es unknown
- 2021-07-21 JP JP2021571463A patent/JP7022873B1/ja active Active
- 2021-07-21 WO PCT/JP2021/027316 patent/WO2022019329A1/ja active Application Filing
- 2021-07-21 TW TW110126744A patent/TW202216140A/zh unknown
-
2022
- 2022-02-07 JP JP2022017469A patent/JP2022060295A/ja active Pending
-
2023
- 2023-01-20 CL CL2023000199A patent/CL2023000199A1/es unknown
- 2023-02-20 ZA ZA2023/02083A patent/ZA202302083B/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR102566299B1 (ko) | 2023-08-10 |
WO2022019329A1 (ja) | 2022-01-27 |
JP7022873B1 (ja) | 2022-02-18 |
US20230270730A1 (en) | 2023-08-31 |
TW202216140A (zh) | 2022-05-01 |
CN115803024A (zh) | 2023-03-14 |
ZA202302083B (en) | 2023-10-25 |
CR20230095A (es) | 2023-03-29 |
JP2022060295A (ja) | 2022-04-14 |
AU2021311665A1 (en) | 2023-03-16 |
BR112023000883A2 (pt) | 2023-02-07 |
JPWO2022019329A1 (es) | 2022-01-27 |
KR20230003296A (ko) | 2023-01-05 |
MX2023000857A (es) | 2023-02-15 |
IL300051A (en) | 2023-03-01 |
KR20230122174A (ko) | 2023-08-22 |
EP4186506A1 (en) | 2023-05-31 |
CA3186655A1 (en) | 2022-01-27 |
CL2023000199A1 (es) | 2023-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20231094A1 (es) | Composicion que contiene un derivado de arilamida | |
PE20231081A1 (es) | Derivados de quinoxalina como farmacos contra el cancer | |
CO2022004686A2 (es) | Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo | |
PE20230239A1 (es) | Derivado de arilamida con actividad antitumoral | |
MX2021000795A (es) | Compuestos heterociclicos para inhibir la actividad de shp2. | |
AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
MX2020007014A (es) | Compuestos de benzamida. | |
ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
AR074352A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatitis atopica. | |
AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
AR054482A1 (es) | Derivados de azetidinona para el tratamiento de hiperlipidemias | |
RU2008107765A (ru) | Макроциклические ингибиторы вируса гепатита с | |
CO6321269A2 (es) | Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios | |
EA201600403A1 (ru) | N-ацилиминогетероциклические соединения | |
PE20070829A1 (es) | Inhibidores cetp heterociclicos | |
RU2014145819A (ru) | Бициклическое соединение | |
AR105929A1 (es) | Derivados de 2-difluorometil-nicotin(tio)carboxanilida sustituidos y su uso como fungicidas | |
AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 | |
HRP20231475T1 (hr) | Derivat p-fenilendiamina kao regulator kalijevih kanala i postupak priprave i njegova medicinska primjena. | |
MY194004A (en) | 4 -substituted benzoxaborole compounds and uses thereof | |
MX2021011286A (es) | Compuestos de heterociclil(fenil)metanol útiles en el tratamiento de la hiperglucemia. | |
NI201800063A (es) | Compuesto de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer | |
AR106475A1 (es) | Derivados de piridina o de pirimidina | |
RU2008143546A (ru) | Тиазолилдигидрохиназолины | |
RU2008128566A (ru) | Органические соединения |